机器狗定制化开发

Search documents
锦富技术接受调研 机器人业务多领域推进
Zheng Quan Shi Bao Wang· 2025-06-03 11:42
Group 1 - The core viewpoint of the articles highlights the ongoing focus on the robotics sector, with Jinfu Technology (300128) detailing its advancements in the field and outlining three main directions for commercializing its robotics business: testing, complete line OEM, and secondary development [1][2] - Jinfu Technology has defined three business directions in the robotics field: 1) In the testing area, the company is collaborating with various domestic and international robot manufacturers, expecting orders to materialize within the year; 2) In complete line OEM, its subsidiary, Maizhi Technology, is deeply involved in product development for a U.S. educational robotics company, aiming to expand its overseas market presence; 3) In secondary development, the company is customizing solutions based on mainstream robotic dog manufacturers for specific applications [1][2] - The company emphasizes that there are currently no standardized testing processes in the robotics industry, and it is working with leading robot companies to explore testing standards, leveraging its unique advantages in optical visual inspection and intelligent testing [2] Group 2 - Jinfu Technology is actively optimizing its industrial layout by divesting non-core business segments and concentrating resources on high-tech sectors such as new materials and robotics, aligning with industry development trends to foster new productive forces [3] - The policy support and rapid development of humanoid robots are expanding the commercial space for robotics, with the Ministry of Industry and Information Technology's "14th Five-Year Plan" setting a target of 500 industrial robots per 10,000 people by 2025, doubling from 2020 [2] - According to Tianfeng Securities, the global humanoid robot market is projected to grow from $2.16 billion in 2023 to $20.6 billion by 2029, with a compound annual growth rate of 57%, indicating that related industry chain companies will benefit in the long term [2]